The healthcare sector is grappling with an escalating threat from an insidious germ that’s proving tough to combat. Infections induced by NDM-producing carbapenem-resistant Enterobacterales (CRE), bacteria notorious for their ability to resist even our most potent antibiotics, have skyrocketed recently. A recent, peer-reviewed examination reveals as astounding 460 percent hike in such cases from 2019 to 2023. In 2020 alone, the Centers for Disease Control and Prevention (CDC) reported an estimated 12,700 cases of CRE infections and 1,100 associated fatalities in the United States, portending the steep rise we’re witnessing today. This worrisome data has been brought to light by Danielle Rankin and her diligent team from the Division of Healthcare Quality Promotion that notches resistant germs through nationwide surveillance and dedicated public health labs.
The troublesome germ in question, NDM-CRE, is a subset of the enterobacterales bacterial family, notorious for their resistance to carbapenem-class antibiotics. Their secret weapon is an enzyme called New Delhi metallo-beta-lactamase (NDM), which allows them to neutralize many beta-lactam drugs simultaneously. NDM’s efficacy starkly contrasts with other similar enzymes, like carbapenemases, against which many antibiotics have managed to retain their potency.
The resistance genes of these bacteria often reside within plasmids, small DNA loops that can transfer between bacteria, enabling the resistance trait to proliferate across different species and contaminate multiple facilities. These infections are not minor inconveniences but serious threats, with mortality rates for CRE infections registering between 26 and 44 percent, according to a recent narrative review.
NDM producers are capable of causing an array of dangerous infections including pneumonia, bloodstream, urinary tract, and wound infections, the severity of which can rapidly intensify. At-risk are patients admitted in intensive care, transplant recipients, and those on long hospital stays. The crux of the issue resides in the difficulty in identifying the specific carbapenemase involved in the resistance, delaying appropriate treatment and the spread of the bacteria.
Healthcare providers are armed with an array of phenotypic assay and molecular tests to confirm the presence of the bacteria and its resistance gene, with expertise provided by CDC’s AR Lab Network where hospital labs lack the ability. A diligent approach to testing is paramount for it influences therapy choices, helps recognize infection clusters, ensures patient isolation, and alerts facilities in the event of patient transfers.
Treatment choices for NDM producers are challenging due to the range of resistance, but current recommendations lean towards intravenous treatments of cefiderocol or a combination of aztreonam with ceftazidime avibactam, especially for metallo beta lactamase producers. These options, however, are not universally applicable.
In the fight against these menacing infections, traditional tools like hand hygiene, dedicated equipment, and environmental sanitation still wield considerable power and are irreplaceable in CDC’s infection control guidance. Effective antimicrobial stewardship also plays a vital role as indiscriminate antibiotic use can naturally select for resistant strains. Facilities need to be equipped with broader screening capabilities and faster testing protocols. Public health labs can help facilities marred by lack of capacity and regional data can guide resource allocation and coordination across networks. All these measures are to realize one simple objective: to reduce infections, decrease hospital stays, and salvage lives using shrewd diagnostics, judicious therapy choices, and steadfast infection control norms.
Source: https://www.earth.com/news/hospitals-face-mounting-crisis-as-superbug-infections-spread-unchecked/